Market Access Blog

blog-graphics-for-website-1

Immunology Day

Today is the annual International Day of Immunology. That might once have been largely of interest to immunologists, but we are all immunologists now. The arrival of SARS-CoV-2 has changed the way the world looks at immunology.

The Day of Immunology is dedicated to increasing global awareness of the importance of immunology in the fight against infection, autoimmunity and cancer. This year, the European Federation of Immunological Societies (EFIS) and the International Union of Immunological Societies (IUIS) are marking the occasion by hosting a webinar that brings global experts together to discuss “Science, State and Challenges of COVID-19 Vaccines.”

The theme of the webinar is vaccines, but vaccines – although they have been very much centre stage in recent years – are only one aspect of the vast field of immunology.

MAP helps companies understand and manage the access environment for drugs that target the immune system. We can provide pricing-strategy support for managing biosimilar entrants or optimising a company’s price versus competitors. We can provide immunology market insights from previous HTA submissions, identifying obstacles to success and strategy to mitigate risks.

The International Day of Immunology’s IUIS–EFIS webinar on vaccines provides a fascinating glimpse at the current state of the art, opening with a look at the Landscape of COVID-19 vaccines from Seth Barkley, CEO of Gavi. Gavi, the international vaccine alliance set up with the goal of increasing access to immunization in poor countries, held a summit entitled Break COVID Now at the beginning of April. The summit saw world leaders commit US$4.8 billion to help Break COVID Now.

Welcoming the support, Professor Jose Manuel Barrosso, Gavi Board Chair, reminded delegates at the summit that the pandemic was far from over. “While gaps in coverage remain, it will continue to wreak havoc on individuals, communities, and economies. Achieving equity is the key to breaking COVID now. We cannot afford to wait and risk the virus undoing all the progress that has been made.”

MAP follows progress on COVID-19 vaccines via its daily news service and runs a regular COVID-19 Update, monitoring news reports from the countries represented by MAP Online.

More information on MAP's expertise in this area can be found here.

COVID-19 Update, 25 April 2022 https://mapbiopharma.online/go#adpbg

New COVID-19 advisory group https://mapbiopharma.online/go#wwerj

Belgium formalises accelerated access for COVID-19 treatment https://mapbiopharma.online/go#swssy

Previous Blog
8 / 41
Next Blog
Arrow Vector-Quotes